Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system

被引:9
|
作者
Zhang, Ying [1 ]
Ran, Li [1 ]
Liang, Yongchao [1 ]
Zhang, Yanqiu [1 ]
An, Zhuoling [1 ]
机构
[1] Capital Med Univ, Beijing Chao Yang Hosp, Dept Pharm, Beijing, Peoples R China
关键词
pemigatinib; Food and Drug Administration adverse event reporting system; disproportionality analysis; real-word study; Advers drug events; PHASE-II; METASTATIC CHOLANGIOCARCINOMA; PATIENTS PTS; OPEN-LABEL; IN-VIVO; HYPOPHOSPHATEMIA; MULTICENTER; EXPRESSION; INHIBITORS; BGJ398;
D O I
10.3389/fphar.2023.1194545
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Cholangiocarcinoma (CCA) is a highly lethal and aggressive epithelial tumor of the hepatobiliary system. A poor prognosis, propensity for relapse, low chance of cure and survival are some of its hallmarks. Pemigatinib, the first targeted treatment for CCA in the United States, has been demonstrated to have a significant response rate and encouraging survival data in early-phase trials. The adverse events (AEs) of pemigatinib must also be determined.Objective: To understand more deeply the safety of pemigatinib in the real world through data-mining of the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).Methods: Disproportionality analysis was employed in a retrospective pharmacovigilance investigation to identify the AEs linked to pemigatinib use as signals. Data were collected between 1 January 2020 to 30 June 2022. Four data-mining methods (proportional reporting odds ratio; proportional reporting ratio; Bayesian confidence propagation neural networks of information components; empirical Bayes geometric means) were used to calculate disproportionality.Results: A total of 203 cases using pemigatinib as the prime-suspect medication were found in our search, which involved 99 preferred terms (PTs). Thirteen signals of pemigatinib-induced AEs in seven System Organ Classes were detected after confirming the four algorithms simultaneously. Nephrolithiasis was an unexpected significant AE not listed on the drug label found in our data-mining. Comparison of the differences between pemigatinib and platinum drugs in terms of 33 PTs revealed that 13 PTs also met the criteria of the four algorithms. Ten of these PTs were identical to those compared with all other drugs, in which (excluding a reduction in phosphorus in blood) other PT signal values were higher than those of all other drugs tested. However, comparison of the differences between pemigatinib and infigratinib in terms of the 33 PTs revealed no significant signals in each algorithm method.Conclusion: Some significant signals were detected between pemigatinib use and AEs. PTs with apparently strong signals and PTs not mentioned in the label should be taken seriously.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS)
    Thomas J. Moore
    Richard L. Morrow
    Colin R. Dormuth
    Barbara Mintzes
    Pharmaceutical Medicine, 2020, 34 : 135 - 140
  • [2] US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS)
    Moore, Thomas J.
    Morrow, Richard L.
    Dormuth, Colin R.
    Mintzes, Barbara
    PHARMACEUTICAL MEDICINE, 2020, 34 (02) : 135 - 140
  • [3] The safety of niacin in the US Food and Drug Administration Adverse Event Reporting database
    Alsheikh-Ali, Alawi A.
    Karas, Richard H.
    AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (8A): : 9B - 13B
  • [4] Comparison of the safety profiles for pirfenidone and nintedanib: a disproportionality analysis of the US food and drug administration adverse event reporting system
    Sun, Xiangyu
    Wang, Huaguang
    Zhan, Xi
    Yan, Yuanyuan
    Chen, Kun
    An, Zhuoling
    Zhou, Hong
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [5] Cardiovascular safety profile of romosozumab: A pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system (FAERS)
    Kvist, Annika
    Faruque, Junaid A. Y.
    Burden, Andrea M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 159 - 160
  • [6] Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Kvist, Annika Vestergaard
    Faruque, Junaid
    Vallejo-Yague, Enriqueta
    Weiler, Stefan
    Winter, Elizabeth M.
    Burden, Andrea M.
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (08)
  • [7] Analysis of Information on Drug Adverse Reactions Using US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Nango, Daisuke
    Sekizuka, Tuyoshi
    Goto, Makoto
    Echizen, Hirotoshi
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2022, 142 (04): : 341 - 344
  • [8] Adverse events reported to the US Food and Drug Administration Adverse Event Reporting System for tisagenlecleucel
    Dores, Graca M.
    Jason, Christopher
    Niu, Manette T.
    Perez-Vilar, Silvia
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (09) : 1087 - 1100
  • [9] Novel Adverse Event of Atezolizumab: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database
    Ahmed, Abdul Mannan Faruk
    Maheswari, Eswaran
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 306 - 306
  • [10] Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system
    Wang, Jun
    Zou, Dongna
    Li, Yuchao
    Liu, Pingping
    Guo, Chenyu
    FRONTIERS IN PHARMACOLOGY, 2023, 14